Xencor, Inc. (NASDAQ:XNCR) Receives $29.50 Consensus Target Price from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have received an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $29.50.

Several equities research analysts recently issued reports on XNCR shares. William Blair started coverage on shares of Xencor in a research note on Monday, April 21st. They issued an “outperform” rating for the company. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Xencor in a research note on Wednesday, April 30th. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Barclays cut their target price on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research note on Thursday, May 8th. Finally, Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th.

Xencor Trading Down 0.9%

Xencor stock opened at $9.43 on Friday. The firm has a 50-day moving average of $9.03 and a 200-day moving average of $15.29. Xencor has a one year low of $7.16 and a one year high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company has a market cap of $671.14 million, a price-to-earnings ratio of -2.95 and a beta of 0.87.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. During the same quarter in the prior year, the company earned ($1.11) earnings per share. The company’s quarterly revenue was up 104.6% on a year-over-year basis. On average, equities analysts expect that Xencor will post -3.68 earnings per share for the current fiscal year.

Insider Buying and Selling at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of the firm’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the transaction, the executive vice president now directly owns 49,169 shares of the company’s stock, valued at approximately $542,334.07. This trade represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.76% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Primecap Management Co. CA increased its holdings in shares of Xencor by 8.6% during the first quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock worth $103,857,000 after purchasing an additional 776,580 shares during the period. Vanguard Group Inc. increased its holdings in shares of Xencor by 5.5% during the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after purchasing an additional 418,040 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Xencor by 2.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company’s stock worth $92,758,000 after purchasing an additional 107,350 shares during the period. BVF Inc. IL increased its stake in Xencor by 19.7% in the first quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company’s stock valued at $29,155,000 after acquiring an additional 451,381 shares during the last quarter. Finally, TCG Crossover Management LLC increased its stake in Xencor by 1.0% in the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company’s stock valued at $56,350,000 after acquiring an additional 25,000 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.